Longboard Pharmaceuticals (LBPH) Commences Share Offering

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $150 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the underwriters a 30-day option to purchase up to an additional approximately $22.5 million of shares of voting common stock. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

Cantor and Citigroup are acting as joint lead book-running managers for the proposed offering, and Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the proposed offering.

The proposed offering is being made pursuant to two shelf registration statements on Form S-3, including base prospectuses, which were previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on October 11, 2022 and August 11, 2023, respectively. A preliminary prospectus supplement and accompanying prospectuses relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectuses relating to the proposed offering, when available, may be obtained from: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York, NY 10022, or by e-mail at [email protected]; or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (800) 831-9146.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• M3-Brigade cancels shareholder meeting after terminating ReserveOne deal
• Pop Culture Group prices $8 million direct offering at $0.15 per share
• Enliven Therapeutics prices upsized public offering at $37.50 per share